NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the company will participate in the following investor conferences:Stephens Annual
Total revenue increased 11% YoY to $209 million
Clinical services revenue grew 13%, with NGS revenue growth of 29%
Company raises full-year 2026 revenue and adjusted EBITDA guidance
NeoGenomics, Inc. (NASDAQ:NEO)
The collaboration is designed to support faster, more informed care for patients and providers
NeoGenomics, Inc. (NASDAQ:NEO), a provider of oncology diagnostic solutions that enable precision medicine across the
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2026 financial results after the close of the
Warren Stone, current President and COO, to become CEO and a member of the Board effective January 4, 2027Tony Zook to remain CEO through January 3, 2027, and become Executive Chairman effective January 4, 2027Lynn
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that the Company will participate in the Morgan Stanley 24th Annual Global Healthcare
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic
Total revenue increased 11% YoY to $202 million
Clinical services revenue grew 14%, with NGS revenue growth of 26%
Company raises full-year 2026 revenue and adjusted EBITDA guidance
NeoGenomics, Inc. (NASDAQ:NEO)
NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has finalized a civil settlement with the Department
Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx identifies patients who may be eligible for TRUQAP®
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2026 financial results after the close of U.S.
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.
Ms. Starrett brings
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today the pricing of its previously announced private offering of $275 million aggregate
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of
Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
